The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity
Abstract
Idiosyncratic DILI from prescription medications and herbal and dietary supplements has an annual incidence rate of approximately 20 cases per 100,000 per year. However, the risk of DILI varies greatly according to the drug. In the US and Europe antimicrobials are the commonest implicated agents, with amoxicillin/clavulanate the most common, while in Asian countries herbal and dietary supplements predominate. Several demographic factors are associated with the risk of DILI as well as the severity and outcome. Genetic analysis of DILI is currently limited but multiple polymorphisms of HLA genes and genes involved in drug metabolism and transport have been identified as risk factors for DILI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Amoxicillin-clavulanate is the most common medication to be implicated with idiosyncratic DILI in the US and Western countries, while anti-tuberculosis medications are the most commonly implicated medications in Asia, along with HDS.[17]”
From Drug-induced liver injury: Diagnosis, management and the role of liver transplantation (2025) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Björnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Navarro, V. J., Barnhart, H., Bonkovsky, H. L., Davern, T., Fontana, R. J., Grant, L., Reddy, R. K., Seeff, L. B., Serrano, J., Sherker, A. H., et al. (2014) · Hepatology · doi:10.1002/hep.27317 · Cited by 418 · cited 1×
“5%) DILI cases were caused by HDS and the incidence appeared to be increasing (15).”
Andrade, R. J., Lucena, I. M., Kaplowitz, N., García-Muņoz, B., Borraz, Y., Pachkoria, K., García-Cortés, M., Fernández, C. M., Pelaez, G., Rodrigo, L., et al. (2006) · Hepatology · doi:10.1002/hep.21424 · Cited by 309
Research works printed but not linked: 69
- Zhang, 2012, Pharmacogenetics of drugs withdrawn from the market, Pharmacogenomics, 13, 223, 10.2217/pgs.11.137 · DOI
- Sgro, 2002, Incidence of drug-induced hepatic injuries: a French population-based study, Hepatology, 36, 451, 10.1053/jhep.2002.34857 · DOI · Paper page
- Suk, 2012, A prospective nationwide study of drug-induced liver injury in Korea, Am J Gastroenterol, 107, 1380, 10.1038/ajg.2012.138 · DOI · Paper page
- de Abajo, 2004, Acute and clinically relevant drug-induced liver injury: a population based case-control study, Br J Clin Pharmacol, 58, 71, 10.1111/j.1365-2125.2004.02133.x · DOI · Paper page
- Ruigómez, 2014, Ascertainment of acute liver injury in two European primary care databases, Eur J Clin Pharmacol, 70, 1227, 10.1007/s00228-014-1721-y · DOI
- De Valle, 2006, Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic, Aliment Pharmacol Ther, 24, 1187, 10.1111/j.1365-2036.2006.03117.x · DOI · Paper page
- Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
- Andrade, 2005, Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period, Gastroenterology, 129, 512, 10.1016/j.gastro.2005.05.006 · DOI · Paper page
- Takikawa, 2009, Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006, Hepatol Res, 39, 427, 10.1111/j.1872-034X.2008.00486.x · DOI · Paper page
- Wai, 2006, Presentation of drug-induced liver injury in Singapore, Singapore Med J, 47, 116
- Bessone, 2016, The Latin American DILI registry experience: a successful ongoing collaborative strategic initiative, Int J Mol Sci, 17, 313, 10.3390/ijms17030313 · DOI
- Björnsson, 2012, Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing, J Hepatol, 56, 374, 10.1016/j.jhep.2011.07.023 · DOI · Paper page
- Charles, 2005, Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization, Am J Med, 118, 618, 10.1016/j.amjmed.2005.02.008 · DOI
- Robles-Diaz, 2015, Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids, Aliment Pharmacol Ther, 41, 116, 10.1111/apt.13023 · DOI · Paper page
- Lucena, 2009, Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex, Hepatology, 49, 2001, 10.1002/hep.22895 · DOI · Paper page
- Hunt, 2014, Age-related differences in reporting of drug-associated liver injury: data-mining of WHO safety report database, Regul Toxicol Pharmacol, 70, 519, 10.1016/j.yrtph.2014.09.007 · DOI
- Molleston, 2011, Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study, J Pediatr Gastroenterol Nutr, 53, 182, 10.1097/MPG.0b013e31821d6cfd · DOI
- Murray, 2008, Drug-related hepatotoxicity and acute liver failure, J Pediatr Gastroenterol Nutr, 47, 395, 10.1097/MPG.0b013e3181709464 · DOI
- Fontana, 2014, Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset, Gastroenterology, 147, 96, 10.1053/j.gastro.2014.03.045 · DOI · Paper page
- Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 · DOI · Paper page
- Vuppalanchi, 2014, Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome, Clin Gastroenterol Hepatol, 12, 1550, 10.1016/j.cgh.2013.12.016 · DOI
- Lammert, 2010, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events, Hepatology, 51, 615, 10.1002/hep.23317 · DOI · Paper page
- Meier, 2005, Incidence of drug-induced liver injury in medical inpatients, Eur J Clin Pharmacol, 61, 135, 10.1007/s00228-004-0888-z · DOI · Paper page
- Chalasani, 2004, Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity, Gastroenterology, 126, 1287, 10.1053/j.gastro.2004.02.015 · DOI · Paper page
- Lewis, 2007, Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial, Hepatology, 46, 1453, 10.1002/hep.21848 · DOI · Paper page
- Wong, 2000, Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection, Hepatology, 31, 201, 10.1002/hep.510310129 · DOI · Paper page
- Lee, 2005, Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy, Chest, 127, 1304
- den Brinker, 2000, Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection, AIDS, 14, 2895, 10.1097/00002030-200012220-00011 · DOI · Paper page
- Sulkowski, 2002, Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections, Hepatology, 35, 182, 10.1053/jhep.2002.30319 · DOI · Paper page
- Kramer, 2005, Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era, J Hepatol, 42, 309, 10.1016/j.jhep.2004.11.017 · DOI
- Kalow, 1987, Genetic variation in the human hepatic cytochrome P-450 system, Eur J Clin Pharmacol, 31, 633, 10.1007/BF00541288 · DOI
- Huang, 2002, Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis, Hepatology, 35, 883, 10.1053/jhep.2002.32102 · DOI · Paper page
- Sharma, 2014, Genetic polymorphisms of CYP2E1 and GSTM1 loci and susceptibility to anti-tuberculosis drug-induced hepatotoxicity, Int J Tuberc Lung Dis, 18, 588, 10.5588/ijtld.13.0344 · doi:10.5588/ijtld.13.0344
- Gupta, 2013, Association of GST null genotypes with anti-tuberculosis drug induced hepatotoxicity in Western Indian population, Ann Hepatol, 12, 959, 10.1016/S1665-2681(19)31302-X · DOI
- Chatterjee, 2010, GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs, J Clin Pharm Ther, 35, 465, 10.1111/j.1365-2710.2009.01101.x · DOI
- Huang, 2003, Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis, Hepatology, 37, 924, 10.1053/jhep.2003.50144 · DOI · Paper page
- Bose, 2011, Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis, J Gastroenterol Hepatol, 26, 312, 10.1111/j.1440-1746.2010.06355.x · DOI
- An, 2012, NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients, Clin Exp Pharmacol Physiol, 39, 535, 10.1111/j.1440-1681.2012.05713.x · DOI
- Lee, 2010, NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis, Int J Tuberc Lung Dis, 14, 622
- Wang, 2012, NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis, Int J Tuberc Lung Dis, 16, 589, 10.5588/ijtld.11.0377 · DOI
- Chen, 2015, Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort, Tuberculosis (Edinb), 95, 68, 10.1016/j.tube.2014.11.004 · DOI
- Nanashima, 2012, Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients, Tuberculosis (Edinb), 92, 253, 10.1016/j.tube.2011.12.004 · DOI
- Chang, 2012, UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications, Int J Tuberc Lung Dis, 16, 376, 10.5588/ijtld.11.0404 · DOI
- Zazuli, 2015, Polymorphism of PXR gene associated with the increased risk of drug-induced liver injury in Indonesian pulmonary tuberculosis patients, J Clin Pharm Ther, 40, 680, 10.1111/jcpt.12325 · doi:10.1111/jcpt.12325
- Gao, 2012, HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients, AIDS Res Hum Retroviruses, 28, 540, 10.1089/aid.2011.0107 · doi:10.1089/aid.2011.0107
- Phillips, 2013, Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa, J Acquir Immune Defic Syndr, 62, e55, 10.1097/QAI.0b013e31827ca50f · doi:10.1097/qai.0b013e31827ca50f
- Carr, 2013, Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population, Clin Infect Dis, 56, 1330, 10.1093/cid/cit021 · DOI
- Spraggs, 2011, HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer, J Clin Oncol, 29, 667, 10.1200/JCO.2010.31.3197 · DOI · Paper page
- Spraggs, 2012, Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes, Clin Pharmacol Ther, 91, 647, 10.1038/clpt.2011.277 · DOI
- Schaid, 2014, Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury, J Clin Oncol, 32, 2296, 10.1200/JCO.2013.52.9867 · DOI
- Hirata, 2008, Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study, Pharmacogenomics J, 8, 29, 10.1038/sj.tpj.6500442 · DOI · Paper page
- Cornejo Castro, 2015, HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity: a systematic review of the literature and meta-analysis, Pharmacogenet Genomics, 25, 186, 10.1097/FPC.0000000000000124 · DOI
- Samara, 2014, Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients, Int J Clin Pharmacol Ther, 52, 746, 10.5414/CP202098 · doi:10.5414/cp202098
- Adam de Beaumais, 2011, Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy, Br J Clin Pharmacol, 71, 575, 10.1111/j.1365-2125.2010.03867.x · doi:10.1111/j.1365-2125.2010.03867.x
- Karathanasis, 2011, The role of the methylenetetrahydrofolate reductase 677 and 1298 polymorphisms in Cretan children with acute lymphoblastic leukemia, Genet Test Mol Biomarkers, 15, 5, 10.1089/gtmb.2010.0083 · doi:10.1089/gtmb.2010.0083
- Mazor, 2013, Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease, Curr Drug Saf, 8, 181, 10.2174/15748863113089990033 · doi:10.2174/15748863113089990033
- Agúndez, 2011, Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity, Expert Opin Drug Metab Toxicol, 7, 817, 10.1517/17425255.2011.574613 · DOI
- Lucena, 2008, Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury, Hepatology, 48, 588, 10.1002/hep.22370 · DOI · Paper page
- Jiang, 2015, Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population, Pharmacogenomics J, 15, 326, 10.1038/tpj.2014.75 · DOI
- Ulzurrun, 2014, Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort, PLoS One, 9, e94675, 10.1371/journal.pone.0094675 · DOI
- Horinouchi, 2010, Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma, Pediatr Hematol Oncol, 27, 344, 10.3109/08880011003739422 · doi:10.3109/08880011003739422
- Nicoletti, 2016, HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury, Pharmacogenet Genomics, 26, 218, 10.1097/FPC.0000000000000209 · DOI
- Parham, 2016, Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01, Pharmacogenomics J, 16, 180, 10.1038/tpj.2015.40 · DOI
- Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 · DOI · Paper page
- Daly, 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat Genet, 41, 816, 10.1038/ng.379 · DOI · Paper page
- Singer, 2010, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury, Nat Genet, 42, 711, 10.1038/ng.632 · DOI · Paper page
- Kindmark, 2008, Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis, Pharmacogenomics J, 8, 186, 10.1038/sj.tpj.6500458 · DOI · Paper page
- Urban, 2012, Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs, Pharmacogenet Genomics, 22, 784, 10.1097/FPC.0b013e3283589a76 · DOI
- Yip, 2015, Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review, Clin Rev Allergy Immunol, 48, 165, 10.1007/s12016-014-8418-y · DOI
Cited by
Drug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Kesar, V., Channen, L., Masood, U., Grewal, P., Ahmad, J., Roth, N. C., & Odin, J. A. (2022) · Liver Transplantation · doi:10.1002/lt.26260 · Cited by 23
Self-citationAbid, A., Subhani, F., Kayani, F., Awan, S., & Abid, S. (2020) · PLOS ONE · doi:10.1371/journal.pone.0231398 · Cited by 22
Drug-induced liver injury: Diagnosis, management and the role of liver transplantation
Ozturk, N. B., Uskudar, E., Toruner, M. D., Simsek, C., & Gurakar, A. (2025) · Hepatology Forum · doi:10.14744/hf.2024.2024.0003 · Cited by 9
Metadata
- Authors
- Ahmad, J., & Odin, J. A.
- Venue
- Clinics in Liver Disease
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 21
- Issue
- 1
- Pages
- 55-72
- ISSN
- 1089-3261
- PMC
- PMC8290403
- Cited by
- 39
- References
- 4
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity. https://app.cochat.ai/papers/10.1016/j.cld.2016.08.004
- The paper
- Ahmad, J., & Odin, J. A. (2017). Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity. Clinics in Liver Disease. https://doi.org/10.1016/j.cld.2016.08.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.